|
Aug 26
|
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
|
|
Aug 9
|
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
|
|
Jun 20
|
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
|
|
Jun 19
|
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
|
|
Jun 19
|
FDA places partial clinical hold on Zentalis’ trials of azenosertib for cancer
|
|
Jun 18
|
US Equity Markets Close Up Tuesday Following Less-Than-Expected Retail Sales Growth
|
|
Jun 18
|
Top Midday Decliners
|
|
Jun 18
|
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
|
|
Jun 4
|
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
|
|
May 30
|
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
|
|
May 29
|
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
|
|
May 14
|
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
|
|
May 8
|
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock
|
|
May 8
|
Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...
|
|
May 7
|
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
|
|
Apr 2
|
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
|
|
Dec 27
|
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
|
|
Dec 1
|
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Sep 6
|
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
|
|
Aug 9
|
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
|